Lv41
490 积分 2026-07-23 加入
Assessing Strategies to Mitigate the Effect of Age When Using Fibrosis-4 Index to Screen for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Liver Fibrosis
4天前
已关闭
Diagnostic Accuracy of Noninvasive Tests for Metabolic Dysfunction-associated Steatotic Liver Disease Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study
6天前
已完结
Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways
6天前
已完结
Implementation of a liver health check in people with type 2 diabetes
6天前
已完结
Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events
6天前
已完结
Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis
8天前
已完结
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
12天前
已完结
Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction
12天前
已完结
Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study
12天前
已完结
Non-invasive Identification of Metabolic Dysfunction-associated Steatotic Liver Disease Patients eligible for Resmetirom Treatment
12天前
已完结
皖公网安备34019202002308
